|
To evaluate the in vitro hormonal and growth effects of Gonadotrophin releasing hormone (GnRH) analogue and gonadal steroid hormones on Gynecological tumors, endometrial carcinoma cell lines (CUMC-1A, CUMC-1B and CUMC-1C), Ovarian carcinoma cell lines (SK-OV-3 and CUMC-2), cervical carcinoma cell lines (HeLa, CaSki, and CUMC-3), and choriocarcinoma cell line (Bewo), were incubated with the appropriate doses of GnRH anaglogue, estrogen and progesterone. Hormonal responses of tumor cell lines after each stimulation were measured by radiommunoassay, and cellular proliferative effects were observed. 1. GnRH analogue showed significant inhibitory effect on tumor cell growth in ovarian and endometrial carcinoma cell lines, but showed rather stimulatory effect in choriocarcinoma cell line. 2. GnRH analogue significantly stimulated β-hCG and LH release on choriocarcinoma cell line and some stimulatory effect on β-hCG release in cervical carcinoma cell line, but no hormonal responses were observed in ovarian and endometrial carcinoma cell lines. 3. Progesterone suppressed β-hCG release significantly on choriocarcinoma cell line, but estrogen stimulated β-hCG release. 4. Administration of GnRH analogue to CA-125 producing ovarian carcinoma cell line produced significant decrease of CA-125 release compared to control group. This finding was consistant with the decrease of cellular proliferation in ovarian carcinoma cell lines. 5. Every Gynecological tumor cell lines secreted some amounts of GnRH. The secretary activity were 3 times higher in cervical and endometrial carcinoma cell lines than ovarian carcinoma cell lines. These results led us than GnRH analogue will be important therapeutic aids in hormone dependent tumors, as ovarian and endometrial carcinoma and also helpful to diagnose the recurrent cases of choriocarcinoma. Especially, the reduced cellular growth and decreased CA-125 concentration during GnRH administration might offer a rationale for GnRH analogue in the therapeutic approach to ovarian carcinoma.
|